This content is machine translated Dyslipidemia: "Treat-to-target" Risk-adapted individual LDL-C targets Together with arterial hypertension and diabetes mellitus, lipid metabolism disorders are among the most important modifiable cardiovascular risk factors. In addition to statins, various modern substance classes are now available...…
View Post 3 min This content is machine translated LDL cholesterol Bempedoic acid and cardiovascular outcomes in statin intolerant patients Treatment of elevated LDL cholesterol levels is a central component of modern therapy to reduce the risk of serious cardiovascular events in patients with primary or secondary prevention. However, 7%…
View Post 4 min This content is machine translated CV Health Update 2023 Hypercholesterolemia – Strengthen Cardiovascular Prevention At the hybrid event “CV Health Update 2023,” Prof. Isabella Sudano, MD, Senior Physician, Head of Cardiovascular Risk Factors, Department of Cardiology Heart Center University Hospital Zurich, presented the current…
View Post 7 min This content is machine translated CLEAR Outcomes Study New results on bempedoic acid Statin-intolerant patients represent a difficult patient group to treat in lipid management. Now, with the CLEAR Outcomes study, it has been shown that a therapeutic option with a beneficial effect…
View Post 5 min This content is machine translated Modern lipid management in type 2 diabetes LDL cholesterol reduction in addition to statins To prevent atherosclerosis and the associated risks, consistent treatment of cardiovascular risk factors is recommended – this includes in particular the reduction of elevated LDL cholesterol levels. In addition to…
